Breaking News, Collaborations & Alliances

GreenLight Biosciences, Samsung Biologics Partner to Advance New RNA Covid Vax

Aims to accelerate the production of GreenLight’s vaccine candidate for Phase III clinical trials and commercial scale.

Author Image

By: Charlie Sternberg

Associate Editor

GreenLight Biosciences, a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Samsung Biologics, a global CDMO providing fully integrated end-to-end contract development and manufacturing services, have entered a partnership agreement in which Samsung Biologics will manufacture GreenLight’s messenger RNA COVID-19 vaccine candidate at commercial scale.   The partnership aims to accelerate the production of Gre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters